STCube Submits Clinical Phase 1 Trial Plan for Immuno-Oncology Drug to US FDA

[Asia Economy Reporter Minji Lee] STCube announced on the 20th that it has applied to the US FDA for a Phase 1, multicenter open-label clinical trial plan to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hsTC810 monotherapy in patients with advanced solid tumors.

The company stated, "hsTC810 is a multinational clinical trial, and after applying for clinical trials with the Korea Food and Drug Administration, we additionally applied for clinical trials with the US FDA," adding, "We plan to disclose the information according to disclosure guidelines upon approval of the clinical trial plans by the MFDS and FDA."